Investor Presentation

View our latest Investor Presentation to find the most recent investor-related information

Algernon Pharmaceuticals DMT/Stroke Clinical Program

Watch Here

Company Overview

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Stock Snapshot



Investor Contact Information

Company

Algernon Pharmaceuticals Inc.
1055 West Georgia Street
Suite 1500
Vancouver, BC V6E 4N7
Canada
T: 604-398-4175
info@algernonpharmaceuticals.com

Investor Relations

Christopher Moreau
Chief Executive Officer
T: 604-398-4175
chris@algernonpharmaceuticals.com

Transfer Agent

TSX Trust Company
1066 W. Hastings Street
Suite 1600
Vancouver, BC V6E 3X1
Canada
T: 604-235-3700
inquiries@astfinancial.com